Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru |
| |
| Institution: | 1. Escuela Profesional de Medicina Humana, Universidad Nacional San Antonio Abad del Cusco, Cusco, Peru;2. Grupo Peruano de Investigación Epidemiológica, Unidad para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Perú;3. Unidad de Investigación Clínica y Epidemiológica, Escuela de Medicina, Universidad Peruana Unión, Lima, Peru;4. Universidad Peruana de Ciencias Aplicadas, Facultad de Medicina, Lima, Peru;5. Sociedad Científica de Estudiantes de Medicina de la Universidad Nacional de Piura, Piura, Perú;6. Facultad de Medicina Humana, Universidad Nacional de San Martín, Tarapoto, Peru;7. Universidad Nacional de la Amazonía Peruana, Facultad de Medicina Humana Rafael Donayre Rojas, Iquitos, Loreto, Perú;8. Universidad de San Martín de Porres, Facultad de Medicina Humana, Chiclayo, Lambayeque, Peru;9. Universidad Peruana Union, Escuela de Medicina Humana, Lima, Peru;10. Deparment of Medicine, Clinica Good Hope, Lima, Peru;11. Unidad de Investigación para la Generación de Síntesis de Evidencia en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru;12. Division of Infectious Diseases, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL, USA;13. Peruvian American Medical Society, USA |
| |
| Abstract: | ObjectiveTo evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population.MethodsCross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was used to estimate the associated factors.ResultsData from 3231 individuals were analyzed, 44.1% of whom intended to participate in COVID-19 vaccine clinical trials. Factors associated with the outcome were being male (RPa: 1.25; 95% CI: 1.15–1.35), being from the highlands region (RPa: 1.18; 95% CI: 1.09–1.28) or jungle (RPa: 1.30; 95% CI: 1.15–1.47), having a relative that is a healthcare professional (PRa: 1.16; 95% CI: 1.06–1.28), using a medical source of information (PRa: 1.28; 95% CI: 1.17–1.41), and trusting in the possible effectiveness of vaccines (PRa: 1.40; 95% CI: 1.29–1.51). The main reason for not participating in the trial was the possibility of developing side effects (69.80%).ConclusionThere is an urgent need to generate a perception of safety in COVID-19 vaccine clinical trials, to increase the population's intention to participate in these studies, and to provide evidence-based information about the vaccine. |
| |
| Keywords: | COVID-19 Coronavirus Intention to participate Vaccine Clinical Trial Associated factors |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
